Hypertension Management in Diabetic Patients with Renal Impairment

Initial Treatment and Combination Therapy

The American College of Cardiology and American Heart Association recommend starting with combination therapy using an ARB, such as losartan 50 mg, plus a dihydropyridine calcium channel blocker, such as amlodipine 5 mg, or thiazide-like diuretic as a single-pill combination, targeting blood pressure <130/80 mmHg in diabetic patients with renal impairment 1, 2, 3
Black patients require combination therapy from the outset because monotherapy is insufficient for adequate blood pressure control in this population, particularly when diabetes and renal impairment coexist, as recommended by the American College of Cardiology 1, 2
The European Society of Cardiology and European Society of Hypertension guidelines recommend that initial treatment in most Black patients should be a 2-drug combination comprising a diuretic and calcium channel blocker, either in combination with each other or with an ACE inhibitor or ARB 2

The presence of diabetes with impaired renal function creates a compelling indication for RAS blockade, such as ACE inhibitors or ARBs, as the foundation of therapy, as recommended by the European Heart Journal 4
RAS blockers are more effective at reducing albuminuria than other antihypertensive agents and are recommended as part of the treatment strategy in hypertensive patients with microalbuminuria or proteinuria, with a strength of evidence level of I, according to the European Heart Journal 4

The International Society of Hypertension guidelines recommend low-dose ARB for Black patients as the preferred RAS blocker, with losartan 50 mg daily plus dihydropyridine calcium channel blocker, such as amlodipine 5 mg daily, as the preferred initial regimen 3
Alternative combinations include ARB plus thiazide-like diuretic, such as chlorthalidone 12.5 mg, with a strength of evidence level of IIa, according to the American College of Cardiology 1, 3
The titration strategy involves increasing both medications to full dose, then adding a third component, such as a thiazide-like diuretic or calcium channel blocker, with careful monitoring of blood pressure, renal function, and potassium levels, as recommended by the American College of Cardiology and European Society of Cardiology 3, 5

The target systolic blood pressure is 130-139 mmHg in patients with diabetic or non-diabetic chronic kidney disease, with individualized treatment according to tolerability and impact on renal function, as recommended by the European Heart Journal 4
The American College of Cardiology recommends aiming to achieve target blood pressure within 3 months of treatment initiation, with regular monitoring of blood pressure, renal function, and potassium levels, and adjusting therapy accordingly, with a strength of evidence level of I 3, 5

Monotherapy should never be used in high-risk patients, such as those with diabetes, Black race, and renal impairment, as combination therapy is necessary to achieve adequate blood pressure control, as recommended by the American College of Cardiology and European Society of Cardiology 1, 2, 3
RAS blockade should not be avoided due to race, as the renoprotective benefits in diabetic nephropathy are race-independent and compelling, with a strength of evidence level of I, according to the European Heart Journal 4
Simultaneous use of ACE inhibitor, ARB, and renin inhibitor should be avoided, as this combination is potentially harmful and not recommended, with a strength of evidence level of III, according to the American College of Cardiology 2